FY26 core growth guided to 4-6% with 75bps margin expansion
Agilent reported strong Q4 FY25 results with 7.2% core growth and above-consensus EPS, citing robust demand in pharma (12% growth) and CDMO (40%+ growth). Management guided to a prudent FY26 with 4-6% core revenue growth and 75bps margin expansion, while navigating tariff headwinds, a higher tax rate, and an accelerating replacement cycle. The company highlighted its IGNITE operating system and new product launches as key drivers of share gains. Q4 FY25 revenue of $1.86B grew 7.2% core, beating guidance, with all major end markets showing growth except academia & government.
Buzzberg readFY26 core growth guided to 4-6% with 75bps margin expansionAgilent reported strong Q4 FY25 results with 7.2% core growth and above-consensus EPS, citing robust demand in pharma (12% growth) and CDMO (40%+ growth). Management guided to a prudent FY26 with 4-6% core revenue growth and 75bps margin expansion, while navigating tariff headwinds, a higher tax rate, and an accelerating replacement cycle. The company highlighted its IGNITE operating system and new product launches as key drivers of share gains. Q4 FY25 revenue of $1.86B grew 7.2% core, beating guidance, with all major end markets showing growth except academia & government.Read full analysisCollapse analysis
Agilent reported strong Q4 FY25 results with 7.2% core growth and above-consensus EPS, citing robust demand in pharma (12% growth) and CDMO (40%+ growth). Management guided to a prudent FY26 with 4-6% core revenue growth and 75bps margin expansion, while navigating tariff headwinds, a higher tax rate, and an accelerating replacement cycle. The company highlighted its IGNITE operating system and new product launches as key drivers of share gains. Q4 FY25 revenue of $1.86B grew 7.2% core, beating guidance, with all major end markets showing growth except academia & government.
CDMO (BioVectra) grew over 40% core, driven by GLP-1 and SI RNA demand, with a nearly full order book for FY26.
New products (Infinity Tree, ProIQ LCMS, Alturo column) are driving significant share gains, notably 50%+ growth in single-quad LCMS.
FY26 guidance calls for 4-6% core revenue growth, 75bps op margin expansion, and 5-7% EPS growth, despite a 250bps tax rate headwind.
Revenue$1.861B
reported
EPS$1.59
reported
Gross margin51.8%
reported
Op margin23.8%
reported
What changed this quarter
01
Guidance
FY26 core growth guided to 4-6% with 75bps margin expansion
Guidance · revenue to $7.35B
02
Tariffs
Tariffs fully mitigated in FY26 through task force actions
Q4 FY25 revenue of $1.86B grew 7.2% core, beating guidance, with all major end markets showing growth except academia & government.
03
Demand
CDMO orders robust, capacity expansion on track for 2027
Management emphasized strong execution, broad-based momentum, and a robust pipeline of innovation, while framing FY26 guidance as prudent but positioned for above-peer growth.
04
Product Innovation
ProIQ LCMS drives 50%+ single-quad growth in Q4
New products (Infinity Tree, ProIQ LCMS, Alturo column) are driving significant share gains, notably 50%+ growth in single-quad LCMS.
AI, capex & demand read
AI
Platform & monetization
Management discussed using AI internally to accelerate innovation and operations, such as AI generating 80% of engineering drawings and reducing custom design cycle times by 75%, and agentic AI in order fulfillment to reduce downtime and improve quality. They are also planning to deploy AI in CRM and virtual agents to enhance customer intimacy, but did not discuss AI as a product or revenue driver
Demand
Bookings & conversion
CDMO orders robust, capacity expansion on track for 2027. Management emphasized strong execution, broad-based momentum, and a robust pipeline of innovation, while framing FY26 guidance as prudent but positioned for above-peer growth.
Capex
Investment and capacity
Management raised capital expenditures by $100 million to $500 million for FY26, primarily for incremental NASD (CDMO) capacity and consumable expansion, with new capacity expected to go live in early-to-mid 2027.
Tone · Confident
Management emphasized strong execution, broad-based momentum, and a robust pipeline of innovation, while framing FY26 guidance as prudent but positioned for above-peer growth.
Supply-chain alpha
A1
Agilent's new CTO from Thermo Fisher (TMO) and manufacturing leader from Gilead (GILD) signal a strategic push to bolster R&D and operational efficiency. This could intensify competition in the analytical instruments space.
Agilent's management states pharma reshoring is a significant opportunity, estimating a $1 billion addressable market by 2030. They are in early conversations and expect orders by end of 2026, but this is a long-term, multi-year tailwind.
Agilent's BioVectra CDMO business is driving significant growth, and management has noted robust booking for FY26, with orders largely covering the full year. This signals strong demand for contract peptide manufacturing, particularly for GLP-1s.
“we've got a very robust order book as we enter the year for pretty much the full year”
In Q4, Agilent's 'single-quad LCMS' (ProIQ launch) grew more than 50%, and the Alturo BioInert column ramp is 'an order of magnitude greater' than past launches. This suggests Agilent is winning significant share in the high-growth GLP-1 and oligonucleotide analytical workflow segment.
Thanks Tejas, and hello everyone. Thank you for joining today's call. Before I talk about our results, I want to start by introducing Adam Elenos, our new CFO who officially joined Agilent last week. Adam joins us after distinguished tenure at Amgen. We advanced through a series of finance, strategy and transformation leadership roles over a total of 19 years, most recently serving as Vice President of Investor Relations and Treasurer. I'm looking forward to leveraging Adam's expertise in strategic planning and M&A and its commitment to cross-function collaboration will be invaluable to Agilent in the years ahead. Adam, would you like to say a few words?
Agilent's new CTO from Thermo Fisher (TMO) and manufacturing leader from Gilead (GILD) signal a strategic push to bolster R&D and operational efficiency. This could intensify competition in the analytical instruments space. — Leadership hires from a direct competitor and a major pharma customer indicate Agilent is planning for a more aggressive, innovation-led growth phase.
“Jaydeep Ganguly joined from Gilead to drive world-class manufacturing”
… our deep bench of in-house talent and complemented it with external hires that bring fresh perspective and domain expertise. At an executive level, in addition to Adam, we brought on Megan Henson to lead our HR team to help us build on our strong culture. August Specht, who joined us from Thermo Fisher as our Chief Technology Officer, brings deep scientific knowledge in analytical technologies and a proven ability to lead innovative R&D teams. And most recently, Jaydeep Ganguly joined from Gilead to drive world-class manufacturing while leveraging our global scale to realize increased efficiencies. While these individuals are important and visible additions to our leadership team, all Agilent employees are focused on accelerating the pace of innovation, driving superior execution, and most importantly, delighting our customers. Finally, we are bringing together these foundational strands through our Ignite operating system, our fourth key dimension. We launched Ignite at the start of the year to improve the pace and quality of our execution and to usher in a new mindset that leverages the power of the enterprise to maximize both growth, and stakeholder value. Some examples …
In Q4, Agilent's 'single-quad LCMS' (ProIQ launch) grew more than 50%, and the Alturo BioInert column ramp is 'an order of magnitude greater' than past launches. This suggests Agilent is winning significant share in the high-growth GLP-1 and oligonucleotide analytical workflow segment. — These are high-value, high-margin consumables and instruments; rapid adoption indicates a potential durable share shift in a critical market segment, pressuring competitors.
“August Specht, who joined us from Thermo Fisher as our Chief Technology Officer”
… virtual agents to complement onsite support in select markets to resolve customer issues more quickly. The third dimension is our increased capabilities and level of talent throughout Agilent. We've leveraged our deep bench of in-house talent and complemented it with external hires that bring fresh perspective and domain expertise. At an executive level, in addition to Adam, we brought on Megan Henson to lead our HR team to help us build on our strong culture. August Specht, who joined us from Thermo Fisher as our Chief Technology Officer, brings deep scientific knowledge in analytical technologies and a proven ability to lead innovative R&D teams. And most recently, Jaydeep Ganguly joined from Gilead to drive world-class manufacturing while leveraging our global scale to realize increased efficiencies. While these individuals are important and visible additions to our leadership team, all Agilent employees are focused on accelerating the pace of innovation, driving superior execution, and most importantly, delighting our customers. Finally, we are bringing together these foundational strands through our Ignite operating system, our fourth key dimension. We launched Ignite at …
Agilent's management states pharma reshoring is a significant opportunity, estimating a $1 billion addressable market by 2030. They are in early conversations and expect orders by end of 2026, but this is a long-term, multi-year tailwind.
appreciate that and then a follow up for a guy I think you mentioned that there were some pharma reshoring assumption in your guidance for twenty twenty six how important is that to your forecast any way to put some context or dimensions around that thank you yeah so we're we're we're in in a lot of conversations with some key pharma companies around reshoring and
talking about what it means for their R&D and tech investments. They're focusing on shovels in the ground and their lab equipment needs, and we expect by the end of 26 that we'll get some orders in that area. So we're estimating the opportunity of about $1 billion by 2030, but we're limited in seeing the order benefited at the end of 26. We see an overall $1 billion addressable market opportunity for Agilent by 2030, and we expect about one-third of that. But overall, I think there's upside in the forecast around reshoring.
🍪 Cookies
We use cookies to operate this site and for analytics. Declining won't affect your access to content.